I Immune checkpoint inhibitors combined

- ² with antiangiogenic drugs in the treatment
- **of unresectable locally advanced / distant**
- 4 metastatic esophageal squamous cell
- 5 **Carcinoma:** a systematic review protocol
- 6 Juanjuan Lu¹, Honglin Li², Sisi Chang¹, YahuiZhu¹, Fuyan Gao¹, Shuai Shao²,
- 7 Chunzheng Ma²
- 8 1. Henan University of Traditional Chinese Medicine (Second Clinical Medical
- 9 College)
- 10 2.Henan Provincial Hospital of Traditional Chinese Medicine
- 11 Author: Juanjuan Lu, female, postgraduate student, Henan University of Traditional
- Chinese Medicine (Second Clinical Medical College),
 17739221512,1123516147@qq.com.
- 14 Corresponding author: Honglin Li, female, Doctor degree, attending physician, master
- 15 supervisor, Department of Oncology, Henan Hospital of Traditional Chinese Medicine,
- 16 18801611544,46991701@qq.com.

17 Abstract

18 Background and purpose

19 Esophageal cancer has the seventh highest incidence and sixth highest fatality rate of

- 20 all malignant tumors. It's a type of cancer that has a greater fatality rate than morbidity.
- 21 In the treatment of advanced esophageal and squamous cell carcinoma, targeted and
- 22 NOTE: This preprint epots new research that has not been certified promising and should not be used to guize citical practice.

aim of this research was to examine the effectiveness and safety of immune
checkpoint inhibitors in combination with antiangiogenic medicines in the treatment
of unresectable patients with locally progressed / distant metastatic esophageal
squamous cell carcinoma.

27 Methods

Before April 15, 2022, randomized controlled trials of immune checkpoint inhibitors 28 combined with anti-angiogenic drugs in the treatment of esophageal cancer will be 29 searched on PubMed, Cochrane Library, EMBASE, WebofScience, China Knowledge 30 31 Network, Wanfang Data Knowledge Service Platform, and VIP. The two authors independently extracted the data, checked the data, and used the "bias risk" tool in the 32 33 Cochrane intervention system evaluation manual to independently evaluate the bias 34 included in the study. When the extracted data were similar enough, the Revman5.4 software was used for meta analysis. If the summary data could not be collected for 35 meta analysis, the results would be summarized in a narrative way. 36

37

38 **Discussion**

This paper introduces in detail the systematic review and design method of immune checkpoint inhibitors mixture with antiangiogenic drugs in the treatment of unresectable locally advanced / distant metastatic esophageal squamous cell carcinoma.

43 Systematic review registration

44 The review protocol has been registered in PROSPERO CRD42022324666

45 Background

Esophageal cancer (EC) is a type of malignant tumor principally involving the 46 47 squamous epithelium and columnar epithelium of the esophagus, EC has the seventh incidence rate and the sixth mortality rate^[1]. The prime pathologic patterns of EC are 48 squamous cell carcinoma and adenocarcinoma, while esophageals squamous cell 49 carcinoma (ESCC)make up more than 90% of all EC^[2-3]. According to statistics, there 50 were only 572000 new cases of EC from poles to poles in 2018, of which ESCC 51 accounted for 482000 cases ^[4]. In recent years, the overall morbidity of EC has 52 decreased, but the mortality rate remains high. The total five-year survival rate of 53 patients with EC is only 16%, while the median survival time is less than 1 year ^[5-6]. 54

55

56 The conventional treatment for EC is surgical resection or subresection combined with lymph node dissection, although more than half of ESCC patients are progressed 57 at the time of treatment and cannot receive routine treatment [7-8]. Patients with EC 58 have a 5-year survival rate of fewer than 20% when treated with radiation, 59 chemotherapy, or surgical combination treatment [9]. This demonstrates that there is a 60 critical need to investigate new treatment options for unresectable locally progressed / 61 distant metastatic ESCC. In the treatment of advanced ESCC, targeted and immune 62 checkpoint inhibitors (ICI)have showed promising outcomes in recent years 63 [10].Wang,F et al. [11] showed that canrelizumab combined with apatinib as a 64 second-line treatment of ESCC achieved a good clinical efficacy, and this is also the 65 first randomized controlled trial of the programmed cell death-1 receptor (PD-1) 66

67 inhibitors combined with anti-angiogenesis inhibitors in the therapy of terminal68 ESCC.

69

However, there is yet little evidence to support the use of ICI in combination with antiangiogenic medicines in the treatment of advanced esophageal squamous cell carcinoma. In this study, we'll look at progression-free survival (PFS), overall survival (OS), objective remission rate (ORR), quality of life, and adverse events, as well as the efficacy and safety of ICI paired with anti-angiogenic medicines. To provide clinicians with a solid foundation.

76 Method/design

The method we used will be consistent with the PRISMA-P Statement [12] (see
additional file 1) report, the preferred reporting item for the Systems evaluation and
Meta-analysis program, and has been registered with the International Prospective
Systems Review Registry (PROSPERO), registration number CRD42022324666.
We will use the PICO principle to describe the research problem, as shown in Table 1.

82 Table 1:

Р	Patients with unresectable locally advanced/distant metastatic esophageal squamous cell carcinoma confirmed by histology or cytology
Ι	Immune checkpoint inhibitor in combination with antiangiogenic drugs
С	chemotherapy
0	Overall survival, progression-free survival
Immune checkpoint inhibitors include: PD-1 inhibitors: nivolumab, pembrolizumab, toripalizumab, sintilimab, camrelizumab, tislelizumab Anti-, Pienpilimumab; PD-L1 Inhibitors: Durvalumab, Atezolizumab, Avaluzumab; CTLA-4 Inhibitor: Ipilimumab. Anti-angiogenic drugs include: bevacizumab, recombinant human endostatin, sorafenib, sunitinib, apatinib, anlotinib, fruquintinib, ramucirumab. Chemotherapy drugs include, but are not limited to: fluorouracil, cisplatin, taxane, docetaxel, oxaliplatin, leucovorin, and epirubicin, alone or in combination.	

84

83

85 The study's inclusion as well as exclusion criteria

86 The following criteria will be met by the researches included in this evaluation:

- 87 (1)Patients with unresectable advanced or metastatic ESCC diagnosed
- 88 histologically or cytologically;
- 89 (2)Patients were treated with ICI and antiangiogenic agents;
- 90 (3)At least one of the following outcomes should be reported: OS, PFS, ORR,
- 91 quality of life assessment, and adverse reactions.
- 92 (4) Randomized controlled trials.
- 93 The following criteria will be excluded :
- 94 (1) duplicate publication of data;
- 95 (2) Outcome indicators are not clear or cannot be combined;
- 96 (3) Small cell esophageal carcinoma, esophageal adenocarcinoma, or other
- 97 mixed carcinomas proved by histology or cytology.
- 98 (4) Animal tests.
- 99

100 Outcome measures of the study

101 The ultimate goal of cancer treatment is to help patients manage the progression of the

102 disease and thus live longer. So we chose two primary endpoints:

- 103 (1) PFS: the time from randomization to disease progression or death from any
- 104 cause.
- 105 (2) OS : time from randomization to death.
- 106 Secondary outcome measures included:
- 107 (1) ORR : the proportion of patients whose tumor shrank by a certain amount for
- 108 a certain period of time.

109 (2) Quality of life evaluation: Karnofsky score was adopted.

- 110 (3) Adverse reactions.
- 111

112 **Retrieval strategy**

We will search relevant studies published before April 15, 2022 in PubMed, Cochrane Library, EMBASE, Web of Science, CNKI, Wan fang Data Knowledge Service Platform, and VIP through the combination of subject words and free words, without language restrictions. Also, we will re-conduct the search before the final analysis. Additional file 2 for more detailed Pubmed database search strategy.

118

119 Study selection

120 The two authors (HLL,JJL) will independently search the literature, select the potential studies that meet the inclusion criteria, import the literature management 121 software NoteExpress to delete the duplicate literatures, then read the literature title 122 and abstract, and include the preliminary qualified literatures according to the 123 established criteria. Then, after reading the full text, the literatures will be screened 124 again and the reasons for the exclusion of the full text will be recorded. Then 125 cross-check. If the two parties disagree, we will communicate with the third author 126 (SSC) until consensus is reached to ensure that the included literature is 127 comprehensive and accurate.We will document the selection process in detail in the 128 PRISMA flowchart, see additional file 3. 129

130

131 Data extraction and management

- 132 We will extract the data eventually included in the study according to the pre-designed
- 133 inclusion study feature table (Table 2). Two authors (HLL,JJL) will extract the data
- 134 independently and record the following specific data in the table.
- 135 (1) Study characteristics and methods: first author, publication date,
- 136 randomization, allocation hiding, and median follow-up time.
- 137 (2) Participants: Total number of participants in each group, country, gender, age,
- 138 tumor stage, pathological diagnosis, PD-L1 protein expression level.
- 139 (3) Intervention: specific treatment plan.
- 140 (4) Other data: OS, PFS, ORR, adverse reactions, quality of life assessment, 95%
- 141 confidence interval.
- 142 If the data in the report is missing or unclear, the first author will be contacted by
- 143 email for specific data.
- 144 Table 2:

 Author
 Year
 Country
 Gender
 Number T/C
 Age
 Pathological diagnosis
 Tumor stage
 PD-Ll
 Randomization method
 Allocation hidden
 Wedian follow-up
 Interventions(T)
 Interventions(C)
 95K21
 Outcomes

 145
 T:Therapy group C:Control group CI:Confidence Interval Outcomes:Overall survival, progression-free survival, objective response rate, Quality of life assessment, Merrise reactions.
 Interventions(C)
 95K21
 Outcomes

146

147 **Quality evaluation method**

```
Two authors (HLL,JJL) independently assessed the bias of the included studies using
the "risk of bias" tool in the Handbook of Systematic Review of Cochrane
Interventions <sup>[13]</sup>. A third author (SSC) will be consulted when differences arise.
Each of the following areas will be evaluated: random sequence generation (selection
bias); Allocation hiding (selection bias); Blindness of subjects and intervention
```

implementors (implementation bias);Blind method of outcome evaluators (detection bias);Results data were incomplete (lost to follow-up bias);Selective reporting (reporting bias);Other biases (common other biases: availability of clear inclusion/exclusion criteria; Whether to calculate the sample size; Sample size balance between groups; Whether baseline data are comparable; Financial support and conflict of interest).Each area will be assessed for high risk, low risk, or uncertain risk bias. The evaluation results will be reported on the Risk quality assessment chart.

160

161 Statistical analysis

We will use Revman5.4 software to analyze the data. We will conduct meta analysis 162 only if the participants, interventions and outcome measurements included in the 163 164 study are similar enough. For the analysis of event occurrence time results, we use the Hazard ratio (HR) and its 95% confidence interval (CI)as the effect measure of each 165 study ^[14]. For binary data, we will calculate relative risk (RR) and 95% CI based on 166 the analysis of the number of events and the number of participants in the intervention 167 group and the control group. For consecutive results, if all the results are measured on 168 the same scale, we will summarize the mean difference (MD) between the treatment 169 groups. We will use Cochran Q and I^2 statistics to assess the statistical heterogeneity 170 between trials. When P < 0.10 or $I^2 > 50\%$, it indicates that there is obvious 171 heterogeneity ^[15], then choose the random effect model to analyze the data, otherwise 172 we will use the fixed effect model. If the same study results use different 173 measurement methods, we will use the inverse variance method to calculate 174

standardized mean difference(SMD) and 95%CI, and we will analyze the data based 175 on the mean, standard deviation and number of participants between the intervention 176 177 group and the control group to calculate the mean difference and 95%CI between the treatment group. If we are unable to count the aggregate data for meta analysis, we 178 179 will conduct a narrative summary of the results. When there is significant heterogeneity, we will do a subgroup analysis of the main outcome indicators, such as 180 the selection of immune checkpoint inhibitors. When the sample size is sufficient to 181 support the analysis (randomized controlled trial > 10), we will investigate the 182 183 publication bias of the funnel chart and do sensitivity analysis.

184 Evidence quality assessment

The included outcome indicators were evaluated according to the GRADE tool. The 185 186 GRADE system evaluates evidence grades based on five grading factors (bias risk, indirectness, imprecision, inconsistency, and publication bias), with drop 1 grade to 187 medium quality, drop 2 grade to low quality, drop 3 grade to very low quality. High 188 quality evidence is strong recommendation, low quality and very low quality is weak 189 recommendation. Finally, the quality of evidence is divided into four levels: high 190 quality, medium quality, low quality and very low quality. High quality evidence is 191 strong recommendation, low quality and very low quality is weak recommendation. 192

193 **Discussion**

EC is a global medical and health problem. It is an aggressive malignant tumor. Surgical resection is a radical treatment. However, most of the patients have local advanced/distant metastasis and cannot be treated by surgery when they come to the

197 clinic. Therefore, the prognosis is poor and new treatment methods are urgently needed. Targeted and ICI have been shown to be efficacious in the management of 198 199 advanced esophageal squamous cell carcinoma in recent years. Wang, F et al. [11] were the first to study the combination of PD-1 inhibitors and anti-angiogenic 200 inhibitors in the treatment of advanced ESCC, and the clinical results were 201 encouraging, which would be the beginning of a new therapy. Currently, ICI 202 combined with antiangiogenic agents in the therapy of terminal esophageal squamous 203 cell carcinoma are limited, and there is no systematic evaluation of this new therapy. 204 This study will be the first systematic review of immunocheckpoint inhibitors 205 combined with antiangiogenic agents in the treatment of unresectable locally 206 advanced/distant metastatic esophageal squamous cell carcinoma. 207

208 This article follows PRISMA-P standards and has been registered with the International Registry for Prospective Systems Review (PROSPERO), registration 209 number CRD42022324666. The research and design methods of system evaluation 210 and meta-analysis are introduced in detail, including inclusion/exclusion criteria, 211 outcome indicators, search strategies, study selection, data extraction and 212 management, quality assessment methods, statistical analysis, and the GRADE system 213 evaluation will be used to evaluate the grade of outcome indicators. Our primary 214 objective is to provide reliable data on the efficacy and safety of immunocheckpoint 215 inhibitors combined with antiangiogenic agents in the treatment of advanced 216 esophageal squamous cell carcinoma for scientific use in clinical studies. 217

218 Abbreviations

- 219 EC:Esophageal cancer
- 220 ESCC:Esophageals squamous cell carcinoma
- 221 ICI:Immune checkpoint inhibitors
- 222 PD-1:Programmed cell death-1 receptor
- 223 PFS:Progression-free survival
- 224 OS:Overall survival,
- 225 ORR:Objective remission rate
- 226 PRISMA-P:Preferred Reporting Items for Systematic Review and Meta-Analysis
- 227 Protocols
- 228 CNKI: China National Knowledge Internet
- 229 HR:Hazard ratio
- 230 CI:Confidence interval
- 231 RR:Relative risk
- 232 MD:Mean difference
- 233 SMD:Standardized mean difference

234 **Declarations**

- 235 Ethics approval and consent to participate
- Not applicable.
- 237 **Consent for publication**
- 238 Not applicable.
- 239 Availability of data and materials

240 Not applicable.

241 Competing interests

242 The authors declare that they have no competing interests.

243 Funding

- 244 Henan Provincial Administration of Traditional Chinese Medicine, Henan Provincial
- 245 Traditional Chinese Medicine Scientific Research Special Project, 2022ZY1089, The
- funders had no role in developing the review protocol.

247 Authors' contributions

- 248 This study was primarily conceived by HLL, JJL, and SSC, with JJL writing the first
- 249 draft of the protocol manuscript and rigorously revising it by HLL. SSC, YHZ, FYG,
- 250 SS registered the protocol in the PROSPERO database. CZM reviewed the manuscript.
- All authors have read and approved this agreement for publication.

252 Acknowledgements

- 253 Not applicable.
- 254 Authors' information
- 255 Corresponding author: HLL

256 **References**

- 257 [1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates
- of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi:
- 259 10.3322/caac.21492.
- 260 [2]Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013 Feb 2;381(9864):400-12. doi:

261 10.1016/S0140-6736.

- 262 [3]Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in
- 263 2012. Gut. 2015 Mar;64(3):381-7. doi: 10.1136/gutjnl-2014-308124.
- 264 [4]Arnold M, Ferlay J, van Berge Henegouwen MI, Soerjomataram I. Global burden of oesophageal and gastric cancer
- 265 by histology and subsite in 2018. Gut. 2020 Sep;69(9):1564-1571. doi: 10.1136/gutjnl-2020-321600.
- 266 [5]Fujihara S, Morishita A, Ogawa K, Tadokoro T, Chiyo T, Kato K, Kobara H, Mori H, Iwama H, Masaki T. The angiotensin
- 267 If type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma
- 268 via the AMPKα/mTOR pathway in vitro and in vivo. Oncotarget. 2017 Jan 31;8(5):8536-8549. doi:
- 269 10.18632/oncotarget.14345.
- 270 [6]Li J, Xu J, Zheng Y, Gao Y, He S, Li H, Zou K, Li N, Tian J, Chen W, He J. Esophageal cancer: Epidemiology, risk factors
- 271 and screening. Chin J Cancer Res. 2021 Oct 31;33(5):535-547. doi: 10.21147/j.issn.1000-9604.2021.05.01.
- 272 [7]Tsuchiya N, Kunisaki C, Sato S, Tanaka Y, Sato K, Watanabe J, Takeda K, Kosaka T, Akiyama H, Endo I.
- 273 Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. Langenbecks Arch Surg. 2022 Mar 1.
- doi: 10.1007/s00423-022-02445-4.
- 275 [8]Thoen H, Ceelen W, Boterberg T, Van Daele E, Pattyn P. Tumor recurrence and in-field control after multimodality
- 276 treatment of locally advanced esophageal cancer. Radiother Oncol. 2015 Apr;115(1):16-21. doi:
- 277 10.1016/j.radonc.2015.03.012.
- 278 [9]Samson P, Lockhart AC. Biologic therapy in esophageal and gastric malignancies: current therapies and future
- 279 directions. J Gastrointest Oncol. 2017 Jun;8(3):418-429. doi: 10.21037/jgo.2016.11.13.
- 280 [10]He S, Xu J, Liu X, Zhen Y. Advances and challenges in the treatment of esophageal cancer. Acta Pharm Sin B. 2021
- 281 Nov;11(11):3379-3392. doi: 10.1016/j.apsb.2021.03.008.
- 282 [11]Wang, F., et al., Camrelizumab in combination with apatinib as second-line treatment for advanced esophageal

- squamous cell carcinoma: A single-arm, open-label, phase II study. Journal of Clinical Oncology, 2021. 39(3_suppl): p.
- 284 215-215.
- 285 [12]Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates
- of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi:
- 287 10.3322/caac.21492.
- 288 [13] Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA; Cochrane
- 289 Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias
- 290 in randomised trials. BMJ. 2011 Oct 18;343:d5928. doi: 10.1136/bmj.d5928.
- 291 [14]Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event
- 292 data into meta-analysis. Trials. 2007 Jun 7;8:16. doi: 10.1186/1745-6215-8-16.
- 293 [15]Yu G, Yu W, Xu X, Ye B, Yao L. Neoadjuvant immunotherapy for resectable esophageal cancer: A protocol of
- 294 meta-analysis. PLoS One. 2021 Jun 4;16(6):e0252829. doi: 10.1371/journal.pone.0252829.

295